The following ventures have been selected by the
INCATE Selection Committee

Arivin therapeutics

Tackling resistant infections with virulence inhibition.

Website

INVITRIS

Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.

Website

Myxobiotics

Myxobiotics is a start-up company discovering and developing novel antibiotics from natural products first isolated and characterized from myxobacteria.

smartbax

At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Website

The following ventures were selected
at INCATE pitch events

Limmatech Biologics

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.

Website